Stock Analiz

Angiodynamics Inc. ANGO

Medical/Dental Instruments · IPO 2004 · data as of November 13, 2026

$11.87Market cap $499M
Open the interactive analysis →

Angiodynamics Inc. (ANGO) is a healthcare company listed in the US with a market value of about $499M. In the twelve months to August 31, 2026 it had revenue of $325M and net income of -$33M, a net margin of -10.1%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).

Key numbers: a price to free cash flow of 345.7, 5-year revenue growth of 2% a year, a 5-year average ROIC of -29%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 77% below the current price.

About Angiodynamics

Angiodynamics is listed in the US and classified in medical/dental instruments, IPO year 2004. Revenue went from $354M in 2016 to $320M in 2026, a decline of about 1.0% a year. It was profitable in 3 of the last 10 years in our data. Its share count rose by 5% over three years (dilution for shareholders). It spends 9% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health3/5
Shareholder returns1/5

Checks passed

  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Liabilities below 60% of assets
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF345.7
P/S1.5
P/B3.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield0.3%
Shareholder yield0.0%
Intrinsic value vs. price−77%

Growth and quality

Revenue growth (1 yr)9.5%
Revenue growth (5 yrs, per year)1.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-21.5%
ROIC (5-yr avg.)-28.7%
Profitable years (of last 10)3
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2026202520242023202220212020201920182017
Revenue$325M$320M$292M$304M$339M$316M$291M$264M$271M$262M$350M
Net income-$33M-$37M-$34M-$184M-$52M-$27M-$32M-$167M$61M$16M$5M
Free cash flow$1M$508000-$15M-$31M-$4M-$11M$19M-$22M$34M$39M$53M
EPS (diluted)$-0.78$-0.88$-0.83$-4.59$-1.33$-0.68$-0.82$-4.39$1.64$0.44$0.14
Net margin-10.1%-11.5%-11.6%-60.7%-15.5%-8.4%-10.8%-63.1%22.7%6.2%1.4%
ROIC—-17.9%-21.3%-87.5%-11.4%-5.5%-6.9%-35.6%-0.9%-1.8%-1.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $19.75, 66% above the current price; targets range from $17.00 to $24.00; the consensus rating is “none”; expected EPS is $-0.28 for the fiscal year ending May 31, 2027.

Frequently asked questions

Is Angiodynamics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 77% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Angiodynamics pay a dividend?

Not currently.

Is Angiodynamics a good stock to buy?

We do not give buy or sell advice. Angiodynamics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.